Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Vexed Top Global Biopharmaceutical Executives About COVID-19 Response

Executive Summary

Pfizer, Eli Lilly and Roche bosses say no country was perfect in its response to the coronavirus pandemic and there are lessons to be learnt.

You may also be interested in...



Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut

Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses. 

Coronavirus Notebook: Hearings On Pandemic Treaty Begin, New Risk-Sharing Partnership To Boost COVAX Efforts

Médecins Sans Frontières says the latest draft of the proposed IP waiver must be rejected, and the WHO has suspended supply of Bharat’s COVID-19 vaccine over manufacturing issues. Two EU agencies have issued advice on fourth doses of mRNA vaccines, while GlaxoSmithKline has filed high-dose sotrovimab for patients with suspected Omicron BA.2 infection in Australia.

How Biotech Firms Kept Raw Material Shortages From Affecting Patients During Pandemic

Biogen, Amgen, Lilly and Genentech experts shared tales of impending stockouts, particularly for single-use assemblies, filters and resins, and some of the measures they took to prevent them from causing drug shortages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS146067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel